Abstract
Clostridium perfringens alpha-toxin is thought to be an important agent in gas gangrene, which is a lifethreatening infection with fever, pain, edema, myonecrosis, and gas production. The toxin (370 residues) is composed of an N-terminal domain (1-250 residues, N-domain) in which the catalytic site is found and a C-terminal domain (251-370 residues, C-domain) responsible for binding to membranes. During the past decade, recombinant DNA technology has been employed to develop second-generation vaccines, including site-directed mutants and the C-domain of the toxin, to prevent gas gangrene. These immunities have led to protection against the lethal effects of wild-type C. perfringens in mice. C-domain vaccines are capable of protecting against heterologous clostridia causing clostridial myonecrosis. This article summarizes the current knowledge on vaccines against alpha-toxin.
Keywords: Alpha-toxin, C-domain, Clostridium perfringens, Gas gangrene, Recombinant vaccine.
Current Pharmaceutical Biotechnology
Title:Vaccines against Clostridium perfringens Alpha-toxin
Volume: 14 Issue: 10
Author(s): Masahiro Nagahama
Affiliation:
Keywords: Alpha-toxin, C-domain, Clostridium perfringens, Gas gangrene, Recombinant vaccine.
Abstract: Clostridium perfringens alpha-toxin is thought to be an important agent in gas gangrene, which is a lifethreatening infection with fever, pain, edema, myonecrosis, and gas production. The toxin (370 residues) is composed of an N-terminal domain (1-250 residues, N-domain) in which the catalytic site is found and a C-terminal domain (251-370 residues, C-domain) responsible for binding to membranes. During the past decade, recombinant DNA technology has been employed to develop second-generation vaccines, including site-directed mutants and the C-domain of the toxin, to prevent gas gangrene. These immunities have led to protection against the lethal effects of wild-type C. perfringens in mice. C-domain vaccines are capable of protecting against heterologous clostridia causing clostridial myonecrosis. This article summarizes the current knowledge on vaccines against alpha-toxin.
Export Options
About this article
Cite this article as:
Nagahama Masahiro, Vaccines against Clostridium perfringens Alpha-toxin, Current Pharmaceutical Biotechnology 2013; 14 (10) . https://dx.doi.org/10.2174/1389201014666131226124348
DOI https://dx.doi.org/10.2174/1389201014666131226124348 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Current Neuropharmacology Antibody Delivery Mediated by Recombinant Adeno-associated Virus for the Treatment of Various Chronic and Infectious Diseases
Current Gene Therapy Local Drug Delivery to Inner Ear for Treatment of Hearing Loss
Current Drug Therapy A Developmental Psychopathology Perspective of Obsessive-Compulsive Disorder
Current Psychiatry Research and Reviews Cardiovascular Risk Calculators and their Applicability to South Asians
Current Diabetes Reviews Inhaled Biologics: From Preclinical to Product Approval
Current Pharmaceutical Design TRAIL: A Sword for Killing Tumors
Current Medicinal Chemistry Targeting Gap Junctions: New Insights into the Treatment of Major Depressive Disorder
Current Medicinal Chemistry Prolonged Perfusion Predicts Recurrent Ischemic Stroke but not Transient Ischemic Attack in Patients with Symptomatic Intracranial Stenosis
Current Neurovascular Research Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Application of Chemoinformatic Tools for the Design of Novel Molecules as anti-Parkinsonian Agents
Current Signal Transduction Therapy Drug Discovery: Methods for Identifying New Drug Targets
Drug Design Reviews - Online (Discontinued) Cannabinoid 1 (CB1) Receptor - Pharmacology, Role in Pain and Recent Developments in Emerging CB1 Agonists
CNS & Neurological Disorders - Drug Targets Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Current Pharmaceutical Design Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Glutathione System and its Regulation by Neurohormone Melatonin in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Catatonia in Affective Disorders
Current Psychiatry Reviews P2X Receptors, Sensory Neurons and Pain
Current Medicinal Chemistry Evaluation of microRNA Stability in Plasma and Serum from Healthy Dogs
MicroRNA